Table 2.

Overview of phase 3 trials in r/r-CLL.

Trial	Treatment Arms	ORR	OS	PFS	uMRD
ASCEND [84]	Acb vs. Investigators choice (Idl-R or BR)	81% (Acb) vs. 75%	12-months OS 94% (Acb) vs. 91%	Estimated 12-month PFS 88% (Acb) vs. 68% (Idl-R) or 69% (BR)	N.A.
MURANO [26,128]	Ven-R vs. BR	92% (Ven-R) vs. 72% (BR)	4-year OS 85% (Ven-R) vs. 67% (BR)	4-year PFS 57% (Ven-R) vs. 5% (BR)	N.A.
RESONATE-1 [18,129]	Ibr vs. Ofa	86% (Ibr) vs. 24% (Ofa)	3-year OS 74% (Ibr) vs. 65% (Ofa)	3-year PFS 59% (Ibr) vs. 3% (Ofa)	N.A.

Abbreviations: Acb, acalabrutinib; B, bendamustine; Ibr, ibrutinib; Idl, idelalisib; Ofa, ofatumumab; R, rituximab; Ven, venetoclax; N.A., not available.